**

VIVES Partners Leads €84M Funding Round for Innovative Radiopharmaceutical Company Nuclidium: Revolutionizing Cancer Treatment

The radiopharmaceutical industry is experiencing a period of explosive growth, driven by advancements in targeted therapies and a growing need for improved cancer treatments. This week, VIVES Partners, a leading European healthcare investor, announced a significant investment, spearheading an €84 million Series B funding round for Nuclidium, a groundbreaking company focused on developing and commercializing innovative radiopharmaceuticals. This substantial investment underscores the immense potential of Nuclidium's technology and its ability to disrupt the oncology landscape. The funding will accelerate Nuclidium's clinical development programs and expand its manufacturing capabilities, bringing life-changing therapies closer to patients battling cancer worldwide.

Nuclidium: A Game Changer in Targeted Radiotherapy

Nuclidium is at the forefront of the rapidly expanding field of targeted alpha therapy (TAT) and targeted beta therapy (TBT), utilizing innovative radioisotopes to deliver highly precise radiation directly to cancerous cells, minimizing damage to healthy tissues. This approach represents a significant leap forward compared to traditional radiation therapies, offering the potential for improved treatment efficacy and reduced side effects. This makes it a highly attractive proposition for investors and further fuels interest in precision medicine and oncology investment.

The Significance of the €84 Million Investment

The €84 million Series B funding round, led by VIVES Partners with participation from other undisclosed investors, will be pivotal in propelling Nuclidium's ambitious goals. The funds will be strategically allocated across several key areas:

• Clinical Development: Accelerating the clinical trials of Nuclidium's lead candidates, progressing them through pivotal studies and ultimately securing regulatory approvals. This includes expanding their Phase 2 clinical trials and pushing toward Phase 3 clinical trials for their key products.

• Manufacturing Scale-up: Investing in state-of-the-art manufacturing facilities to ensure the large-scale production and supply of Nuclidium's radiopharmaceuticals. This involves building capacity for Good Manufacturing Practice (GMP) compliant manufacturing and streamlining supply chains.

• Team Expansion: Building a world-class team of scientists, clinicians, and regulatory experts to drive the company's growth and development. This includes hiring in key areas like radiochemistry, clinical development, and regulatory affairs.

• Research and Development: Further advancing Nuclidium's research and development pipeline, exploring new therapeutic applications and expanding its portfolio of radiopharmaceuticals. This underlines their commitment to radiopharmaceutical innovation and the development of novel cancer therapies.

VIVES Partners: A Strategic Partner in Healthcare Innovation

VIVES Partners has a strong track record of investing in innovative healthcare companies, particularly within the oncology sector. Their decision to lead this significant funding round highlights their confidence in Nuclidium's technology and management team. The partnership signifies not only financial support but also access to VIVES Partners' extensive network and expertise in the pharmaceutical and biotechnology industries. This strategic collaboration will be crucial in navigating the complexities of drug development, regulatory approvals, and commercialization. This investment aligns perfectly with VIVES Partners' strategy of supporting companies developing breakthrough cancer treatments and other innovative therapies.

The Future of Radiopharmaceuticals and Targeted Therapy

The investment in Nuclidium underscores a broader trend in the pharmaceutical industry: the increasing focus on targeted therapies and personalized medicine. Radiopharmaceuticals, particularly those utilizing targeted alpha and beta therapies, offer a powerful approach to treating cancer by precisely delivering radiation to tumor cells while sparing surrounding healthy tissue. This minimizes side effects and improves patient outcomes, making them a highly promising area of research and development. The success of Nuclidium will have a significant impact on the future of cancer treatment and radiopharmaceutical development.

Implications for Patients and the Healthcare Industry

The successful development and commercialization of Nuclidium's radiopharmaceuticals hold tremendous potential to improve the lives of cancer patients worldwide. The increased access to highly effective and targeted therapies could lead to significantly better outcomes, improved quality of life, and potentially longer survival rates. The advancements made by Nuclidium will also have a considerable impact on the broader healthcare industry, driving innovation and further investment in the field of radiopharmaceutical development. This signals a significant shift toward personalized oncology and improved treatment options for cancer patients.

Conclusion: A Promising Future for Cancer Treatment

The €84 million investment in Nuclidium represents a significant milestone in the development of innovative cancer therapies. VIVES Partners' leadership in this funding round, coupled with Nuclidium's groundbreaking technology, positions the company for substantial growth and success. The future looks bright for Nuclidium, and the impact on cancer treatment worldwide is poised to be transformative. The company's progress will be closely followed by investors, researchers, and cancer patients alike, eagerly awaiting the next stages of clinical development and the potential for life-changing treatments. This investment is a powerful testament to the future of radiopharmaceutical innovation and its potential to revolutionize oncology.